Loading...
Docoh

PAVmed (PAVM)

Employees
Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 15, 2021, PAVmed Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “2021 Annual Meeting”). Stockholders representing approximately 65.6% of the shares outstanding and entitled to vote were present in person or by proxy. At the 2021 Annual Meeting, the stockholders elected each of management’s nominees for director and approved each of the other matters considered. A description of the matters considered by the stockholders and a tally of the votes on each such matter are set forth below.

1. The election of two Class B directors, to hold office until the third succeeding annual meeting and until their respective successors are duly elected and qualified.

The Company’s board of directors is divided into three classes, Class A, Class B and Class C. There are three directors in Class B, James L. Cox, M.D., Debra J. White and David Weild IV, whose terms expired at the 2021 Annual Meeting, two directors in Class C, Lishan Aklog, M.D. and Michael J. Glennon, whose terms expire at the 2022 annual meeting of stockholders, and two directors in Class A, Ronald M. Sparks and Tim Baxter, whose terms expired at the 2023 annual meeting of stockholders. Upon the expiration of Mr. Weild’s term, the size of Class B was reduced to two members and the size of the board was reduced to six members. Management nominated Dr. Cox and Ms. White for re-election as Class B directors.

Each of management’s nominees for director was elected, as follows:

NameForAuthority WithheldBroker Non-Votes
James L. Cox, M.D.21,301,3827,477,80626,190,104
Debra White25,691,0993,088,08926,190,104

2. A proposal to amend the Company’s 2014 Long-Term Incentive Equity Plan (the “2014 Plan”) (i) to increase total number of shares of the Company’s common stock available under the 2014 Plan by an additional 2,000,000 shares, from 9,951,081 shares to 11,951,081 shares, (ii) to add an “evergreen” provision to automatically increase the number of shares of the Company’s common stock available under the 2014 Plan on January 1st of each year, by an amount equal to 5% of the Company’s outstanding common stock as of December 31st of the preceding fiscal year, or such lesser amount as is approved by the Board, and (iii) to remove the limit on grants to any one participant in any one calendar year, except for non-employee directors.

2



The amendment was approved, as follows:

ForAgainstAbstainBroker Non-Votes
14,587,56513,705,490486,13326,190,104

A fuller description of the 2014 Plan, as amended, is set forth on pages 7 to 14 of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2021 (the “Definitive Proxy Statement”), which description is incorporated herein by reference. The description of the 2014 Plan from the Definitive Proxy Statement does not purport to be complete and is qualified in its entirety by reference to the full text of the 2014 Plan, which is included as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference.

3. A proposal to amend the Company’s Employee Stock Purchase Plan (the “ESPP”) (i) to increase the total number of shares authorized for employee purchase by 500,000 shares, from 750,000 shares to 1,250,000 shares, and (ii) to add an “evergreen” provision to automatically increase the number of shares of the Company’s common stock available under the ESPP on January 1st of each year, by an amount equal to the lesser of (a) 2% of the Company’s outstanding common stock as of December 31st of the preceding fiscal year, and (b) 2,500,000 shares, or such lesser amount as is approved by the Board.

The amendment to the ESPP was ratified and approved, as follows:

ForAgainstAbstainBroker Non-Votes
16,462,40311,965,447351,33826,190,104

A fuller description of the ESPP, as amended, is set forth on pages 15 to 20 of the Definitive Proxy Statement, which description is incorporated herein by reference. The description of the ESPP from the Definitive Proxy Statement does not purport to be complete and is qualified in its entirety by reference to the full text of the ESPP, which is included as Exhibit 10.2 to this current report on Form 8-K and is incorporated herein by reference.

4. A proposal to ratify the appointment of Marcum LLP as the Company’s independent registered certified public accounting firm for the year ending December 31, 2021.

The ratification of the appointment of Marcum LLP was approved, as follows:

ForAgainstAbstainBroker Non-Votes
54,484,117284,146201,029